Adverse events leading to discontinuation or temporary suspension of study treatment administration;Adverse events up to 56 days post-administration of a single dose;Adverse events within 72 hours post-dosing;Pharmacokinetic parameter of area under the concentration-time curve (AUC) from time 0 to infinity;Pharmacokinetic parameter of maximum observed concentration after dosing (Cmax);Pharmacokinetic parameter of observed or estimated concentration at 28 days (C28d) after dosing;Pharmacokinetic parameter of time at (Tmax) which Cmax occurs after dosing;Pharmacokinetics parameter of area under the concentration-time curve (AUC) from time 0 to the last quantifiable concentration (AUC0-last) of SARS-CoV-2 antibodies after dose of COVID-HIG;Serious adverse events up to 56 days post-administration of a single dose

Adverse events leading to discontinuation or temporary suspension of study treatment administration;Adverse events up to 56 days post-administration of a single dose;Adverse events within 72 hours post-dosing;Pharmacokinetic parameter of area under the concentration-time curve (AUC) from time 0 to infinity;Pharmacokinetic parameter of maximum observed concentration after dosing (Cmax);Pharmacokinetic parameter of observed or estimated concentration at 28 days (C28d) after dosing;Pharmacokinetic parameter of time at (Tmax) which Cmax occurs after dosing;Pharmacokinetics parameter of area under the concentration-time curve (AUC) from time 0 to the last quantifiable concentration (AUC0-last) of SARS-CoV-2 antibodies after dose of COVID-HIG;Serious adverse events up to 56 days post-administration of a single dose

Adverse events leading to discontinuation or temporary suspension of study treatment administration;Adverse events up to 85 days post-administration of a single dose;Adverse events within 72 hours post-dosing;Pharmacokinetic parameter of area under the concentration-time curve (AUC) from time 0 to infinity;Pharmacokinetic parameter of maximum observed concentration after dosing (Cmax);Pharmacokinetic parameter of observed or estimated concentration at 28 days (C28d) after dosing;Pharmacokinetic parameter of time at (Tmax) which Cmax occurs after dosing;Serious adverse events up to 85 days post-administration of a single dose

Adverse events leading to discontinuation or temporary suspension of study treatment administration;Adverse events up to 85 days post-administration of a single dose;Adverse events within 72 hours post-dosing;Pharmacokinetic parameter of area under the concentration-time curve (AUC) from time 0 to infinity;Pharmacokinetic parameter of maximum observed concentration after dosing (Cmax);Pharmacokinetic parameter of observed or estimated concentration at 28 days (C28d) after dosing;Pharmacokinetic parameter of time at (Tmax) which Cmax occurs after dosing;Serious adverse events up to 85 days post-administration of a single dose